retatrutide triple hormone receptor agonist obesity meets primary endpoints in two phase III trials, reporting up to 22.6% weight loss – touchENDOCRINOLOGY triple-hormone-receptor agonist retatrutide for obesity
Pay in 4 interest-free payments of $6.17 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9






















